Payment overview · 2025
General Payments
$660.11
34 reported records · 6 companies
Healthcare provider profile · identity verified
Matthew J Deluca, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · BLOOMFIELD, NJ · NPI 1982680302
Verified facts
What the public records show
CMS Open Payments records show Matthew J Deluca, MD received $660.11 in general payments during 2025 across 34 reported records.
Novartis Pharmaceuticals Corporation accounted for 47.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Horizant.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HORIZANT as an associated drug or biological on 2733 records involving 1696 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Horizant by this doctor in 2024.
MDD US Operations, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xadago as an associated drug or biological on 139 records involving 79 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Xadago by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $315.39 | 47.8% | 24 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $116.50 | 17.6% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $109.49 | 16.6% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $90.88 | 13.8% | 6 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $14.33 | 2.2% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.52 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $550.62 | 33 |
| Education | $109.49 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $315.39 | 24 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation, E.R. Squibb & Sons, L.L.C. | $207.38 | 7 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| HORIZANT horizant |
2025 | Horizant | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | HORIZANT open payments reported associated product |
CMS Open Payments — General Payments 2733 supporting records · 1696 recipient NPIs · example record 1242666828 |
Horizant · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| MDD US Operations, LLC Exact reporting entity; no affiliate inference |
2025 | Xadago open payments reported associated product |
CMS Open Payments — General Payments 139 supporting records · 79 recipient NPIs · example record 1241843808 |
Xadago · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 303 | 88 |
| Donepezil Hcl | Donepezil Hcl | 287 | 94 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 202 | 46 |
| Primidone | Primidone | 147 | 41 |
| Levetiracetam | Levetiracetam | 113 | 24 |
| Lamotrigine | Lamotrigine | 85 | 15 |
| Memantine Hcl | Memantine Hcl | 83 | 21 |
| Risperidone | Risperidone | 82 | 16 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 79 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 17 |
| Tramadol Hcl | Tramadol Hcl | 77 | 19 |
| Clonazepam | Clonazepam | 73 | 13 |
| Divalproex Sodium | Divalproex Sodium | 68 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 23 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 66 | 13 |
| Alprazolam | Alprazolam | 60 | suppressed |
| Pregabalin | Pregabalin | 59 | 14 |
| Carbamazepine | Carbamazepine | 54 | 17 |
| Oxcarbazepine | Oxcarbazepine | 54 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 54 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 51 | suppressed |
| Lorazepam | Lorazepam | 48 | 14 |
| Trazodone Hcl | Trazodone Hcl | 48 | 13 |
| Topiramate | Topiramate | 47 | 11 |
| Nuplazid | Pimavanserin Tartrate | 42 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 41 | suppressed |
| Neupro | Rotigotine | 38 | suppressed |
| Xadago | Safinamide Mesylate | 36 | suppressed |
| Dalfampridine Er | Dalfampridine | 35 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Meloxicam | Meloxicam | 33 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 30 | suppressed |
| Phenobarbital | Phenobarbital | 30 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 29 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Rexulti | Brexpiprazole | 25 | suppressed |
| Copaxone | Glatiramer Acetate | 24 | suppressed |
| Entacapone | Entacapone | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 21 | suppressed |
| Rivastigmine | Rivastigmine | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Kesimpta Pen | Ofatumumab | 19 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Lacosamide | Lacosamide | 17 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 17 | suppressed |
| Ubrelvy | Ubrogepant | 17 | suppressed |
| Austedo | Deutetrabenazine | 16 | suppressed |
| Vumerity | Diroximel Fumarate | 16 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 15 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Horizant | Gabapentin Enacarbil | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Ajovy Syringe | Fremanezumab-Vfrm | 11 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $660.11 · 34 records | Novartis Pharmaceuticals Corporation | HORIZANT, KESIMPTA, ZEPOSIA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Horizant play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Azurity Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error